← Browse by Condition
Medical Condition

treatment with second generation bruton 39 s tyrosine kinase inhibitors acalabrutinib zanubrutinib

Total Trials
1
Recruiting Now
1
Trial Phases
Various
NCT07174141
Recruiting

Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study

Enrollment
100 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
View Trial →